OBJECTIVE: Patients with diabetes often have dyslipidemia and increased postprandial lipidmia. Induction of diabetes in LDL receptor (Ldlr(-/-)) knockout mice also leads to marked dyslipidemia. The reasons for this are unclear. RESEARCH DESIGN AND METHODS: We placed Ldlr(-/-) and heterozygous LDL receptor knockout (Ldlr(+/-)) mice on a high-cholesterol (0.15%) diet, induced diabetes with streptozotocin (STZ), and assessed reasons for differences in plasma cholesterol. RESULTS: STZ-induced diabetic Ldlr(-/-) mice had plasma cholesterol levels more than double those of nondiabetic controls. Fast-performance liquid chromatography and ultracentrifugation showed an increase in both VLDL and LDL. Plasma VLDL became more cholesterol enriched, and both VLDL and LDL had a greater content of apolipoprotein (apo)E. In LDL the ratio of apoB48 to apoB100 was increased. ApoB production, assessed using [(35)S]methionine labeling in Triton WR1339-treated mice, was not increased in fasting STZ-induced diabetic mice. Similarly, postprandial lipoprotein production was not increased. Reduction of cholesterol in the diet to normalize the amount of cholesterol intake by the control and STZ-induced diabetic animals reduced plasma cholesterol levels in STZ-induced diabetic mice, but plasma cholesterol was still markedly elevated compared with nondiabetic controls. LDL from STZ-induced diabetic mice was cleared from the plasma and trapped more rapidly by livers of control mice. STZ treatment reduced liver expression of the proteoglycan sulfation enzyme, heparan sulfate N-deacetylase/N-sulfotrasferase-1, an effect that was reproduced in cultured hepatocytyes by a high glucose-containing medium. CONCLUSIONS: STZ-induced diabetic, cholesterol-fed mice developed hyperlipidemia due to a non-LDL receptor defect in clearance of circulating apoB-containing lipoproteins.
OBJECTIVE:Patients with diabetes often have dyslipidemia and increased postprandial lipidmia. Induction of diabetes in LDL receptor (Ldlr(-/-)) knockout mice also leads to marked dyslipidemia. The reasons for this are unclear. RESEARCH DESIGN AND METHODS: We placed Ldlr(-/-) and heterozygous LDL receptor knockout (Ldlr(+/-)) mice on a high-cholesterol (0.15%) diet, induced diabetes with streptozotocin (STZ), and assessed reasons for differences in plasma cholesterol. RESULTS:STZ-induced diabeticLdlr(-/-) mice had plasma cholesterol levels more than double those of nondiabetic controls. Fast-performance liquid chromatography and ultracentrifugation showed an increase in both VLDL and LDL. Plasma VLDL became more cholesterol enriched, and both VLDL and LDL had a greater content of apolipoprotein (apo)E. In LDL the ratio of apoB48 to apoB100 was increased. ApoB production, assessed using [(35)S]methionine labeling in Triton WR1339-treated mice, was not increased in fasting STZ-induced diabeticmice. Similarly, postprandial lipoprotein production was not increased. Reduction of cholesterol in the diet to normalize the amount of cholesterol intake by the control and STZ-induced diabetic animals reduced plasma cholesterol levels in STZ-induced diabeticmice, but plasma cholesterol was still markedly elevated compared with nondiabetic controls. LDL from STZ-induced diabeticmice was cleared from the plasma and trapped more rapidly by livers of control mice. STZ treatment reduced liver expression of the proteoglycan sulfation enzyme, heparan sulfate N-deacetylase/N-sulfotrasferase-1, an effect that was reproduced in cultured hepatocytyes by a high glucose-containing medium. CONCLUSIONS:STZ-induced diabetic, cholesterol-fed mice developed hyperlipidemia due to a non-LDL receptor defect in clearance of circulating apoB-containing lipoproteins.
Authors: Sonia M Najjar; Kelly J Ledford; Simon L Abdallah; Alexander Paus; Lucia Russo; Meenakshi K Kaw; Sadeesh K Ramakrishnan; Harrison T Muturi; Christian K Raphael; Sumona Ghosh Lester; Garrett Heinrich; Sandrine V Pierre; Ralf Benndorf; Veronika Kleff; Ayad A Jaffa; Emile Lévy; Guillermo Vazquez; Ira J Goldberg; Nicole Beauchemin; Rosario Scalia; Süleyman Ergün Journal: Am J Physiol Endocrinol Metab Date: 2013-06-25 Impact factor: 4.310
Authors: Nathalie Gaudreault; Nikit Kumar; Victor R Olivas; Delphine Eberlé; Kyle Stephens; Robert L Raffai Journal: Am J Pathol Date: 2013-10-08 Impact factor: 4.307
Authors: Annas Al-Sharea; Andrew J Murphy; L A Huggins; Y Hu; Ira J Goldberg; Prabhakara R Nagareddy Journal: Atherosclerosis Date: 2018-03-02 Impact factor: 5.162
Authors: David M Maahs; John E Hokanson; Hong Wang; Gregory L Kinney; Janet K Snell-Bergeon; Ashley East; Bryan C Bergman; Irene E Schauer; Marian Rewers; Robert H Eckel Journal: Diabetes Date: 2010-04-14 Impact factor: 9.461
Authors: Federico Biscetti; Giuseppe Straface; Vincenzo Arena; Egidio Stigliano; Giovanni Pecorini; Paola Rizzo; Giulia De Angelis; Luigi Iuliano; Giovanni Ghirlanda; Andrea Flex Journal: Cardiovasc Diabetol Date: 2009-09-08 Impact factor: 9.951